CV

Dr. med. Johannes Brägelmann

Academic education

10/2014 - 10/2017: Masters program „Biostatistics & Medical Biometry“, University of Heidelberg
10/2005 - 06/2012: Medical School, University of Bonn

Scientific degrees

10/2017: Master of Science, University of Heidelberg
06/2014: M.D., University of Bonn, Summa cum laude: „RNA-Seq-based investigation of a viral etiology and prognostic analysis of young patients with oral cancer“ (Supervisor: Prof. Dr. Tanguy Seiwert, Department of Hematology/Oncology, University of Chicago & Prof. Dr. Peter Brossart, Department of Oncology, University Hospital Bonn)
06/2012: Graduation from Medical School, University of Bonn

Scientific career

09/2020 - present: Junior Research Group Leader at the Mildred Scheel School of Oncology Cologne & Department of Translational Genomics, University Cologne
10/2015 - 08/2020: Postdoctoral research fellow, Molecular Pathology, Institute of Pathology and Department of Translational Genomics, University Cologne (Group of Prof. Dr. Martin Sos)
02/2014 - 09/2015: Clinical fellow, Department of Oncology, University Hospital Bonn
12/2012 - 01/2014: Clinical fellow, Department III of Internal Medicine for Cardiology/Pneumology, University Hospital Cologne
03/2009 - 02/2010: Research fellow with Prof. Dr. Tanguy Seiwert, Institute for Hematology/Oncology, University of Chicago

Honors / Awards / Memberships

01/2021: Associated Research Group at the Center for Molecular Medicine Cologne, University Hospital Cologne
08/2019: Second place in the appointment process for the full professorship position (W2) “Molecular Head and Neck Oncology” at the Department of Otolaryngology, University Hospital Cologne
03/2019 - 03/2021: Memorial-Scholarship, Else Kröner-Fresenius-Stiftung 2015: Gerok-Scholarship, University Hospital Bonn
2009 – 2010: Research scholarship, „Studienstiftung des deutschen Volkes“ 2006 – 2012: Scholar of the „Studienstiftung des deutschen Volkes”

10 most relevant publications

  • Brägelmann J, Barahona Ponce C, Marcelain K, Roessler S, Goeppert B, Gallegos I, Colombo A, Sanhueza V, Morales E,Rivera MT, de Toro G, Ortega A, Müller B, Gabler F, Scherer D, Waldenberger M, Reischl E, Boekstegers F, GarateCalderon V, Umu SU, Rounge TB, Popanda O, Lorenzo Bermejo J. Epigenome‐wide analysis of methylation changesin the sequence of gallstone disease, dysplasia, and gallbladder cancer. Hepatology 2020
  • Dammert MA*, Brägelmann J*, Olsen RR*, Böhm S*, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretic L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML. MYC paralog-dependent apoptoticpriming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Comm 2019. *equal contributions
  • Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F,Wolf J, Heukamp L, Sos ML, Heuckmann JM. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clin Cancer Res 2018; 24(6):1337–1343.
  • Brägelmann J*, Dammert MA*, Dietlein F*, Heuckmann JM*, Choidas A*, Böhm S, Richters S, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, VargaZ, Balke-Want H, French CA, Peifer M, Reinhardt HC, Őrfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, KleblBM, Thomas RK, Sos ML. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports 2017; 20(12): 2833–2845. *equal contributions
  • Mollaoglu G*, Guthrie MR*, Böhm S*, Brägelmann J*, Can I, Ballieu PM, Marx A, George J, Heinen C, Chalishazar MD, Cheng H, Ireland AS, Denning KE, Mukhopadhyay A, Vahrenkamp JM, Berrett KC, Mosbruger TL, Wang J, Kohan JL,Salama ME, Witt BL, Peifer M, Thomas RK, Gertz J, Johnson JE, Gazdar AF, Wechsler-Reya RJ, Sos ML, Oliver TG. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuro- endocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell 2017; 31(2): 270–285. *equal contributions
  • Brägelmann J*, Klümper N*, Offermann A*, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer. Clin Cancer Res 2017; 23(7): 1829–1840. *equal contributions
  • Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi R, Buettner R, Shokat KM, McDonald NQ, Kast SK, Gautschi O, Thomas RK, Sos ML. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. ScienceTranslational Med 2017. Vol 9 (394).
  • Mässenhausen A*, Brägelmann J*, Billig H, Vogel W, Kristiansen G, Schröck A, Bootz F, Brossart P, Kirfel J, Perner S. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. IJMS 2017; 18(1):7. *equalcontributions
  • Mässenhausen von A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schröck A, Bootz F,Brossart P, Kirfel J, Heasley L, Brägelmann J*, Perner S*. MERTK as a novel therapeutic target in head and neck cancer. Oncotarget 2016; 7(22): 32678–32694. *equal contributions
  • Brägelmann J, Dagogo-Jack I, Dinali El M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EEW, Seiwert TY. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncology 2013; 49(6):525–533.

Contact Information

Dr. med. Johannes Brägelmann SFB1399
Dr. med. Johannes Brägelmann

Junior Research Group Leader

Mildred Scheel School of Oncology

University Hospital Cologne & Department of TranslationalGenomics

University of Cologne

Curriculum Vitae (CV)

CV